A Phase 3 interventional study of Roflumilast 0.3% cream and Vehicle Cream in Chronic Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 40 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2022-12-07.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 5th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 439 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
12 studies in Psoriasis by Arcutis Biotherapeutics, Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 3, and was the 5th registered.
Arcutis Biotherapeutics, Inc.’s Psoriasis studies by the year they started, since 2017.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
Among Arcutis Biotherapeutics, Inc.’s 12 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive roflumilast cream 0.3% once daily for 8 weeks.
Drug: Roflumilast 0.3% cream
Participants receive vehicle cream once daily for 8 weeks.
Drug: Vehicle Cream
Roflumilast 0.3% cream for topical application.
Also known as: ARQ-151
Vehicle cream for topical application.
Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8
The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
Time frame: Baseline (Day 1) and Week 8
Time to Achieve Psoriasis Area Severity Index-50 (PASI-50)
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only.
Time frame: From start of treatment to achievement of PASI-50 or study completion/early termination (maximum duration = 121 days)
Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75)
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.
Time frame: Baseline (Day 1) and Week 8
Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90)
Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) \[higher scores indicate greater symptom severity\]. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.
Time frame: Baseline (Day 1) and Week 8
Number of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8
The number of participants achieving I-IGA success at Week 8 is presented. Success is defined as achievement of I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8 PLUS a ≥2-grade improvement in score from Baseline. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater symptom severity. Participant counts are based on observed data only.
Time frame: Baseline (Day 1) and Week 8
Number of Participants Achieving Score of 'Clear' in I-IGA at Week 8
The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'); higher scores indicate greater symptom severity.
Time frame: Week 8
Number of Participants Achieving Worst Itch Numerical Rating Score (WI-NRS) Success
The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a ≥ 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score ≥ 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable'), with higher scores indicating greater symptoms severity. Results are based on observed data only.
Time frame: Baseline (Day 1) and Weeks 2, 4, and 8
Change From Baseline in Psoriasis Symptoms Diary (PSD) Score
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement.
Time frame: Weeks 4 and 8
Adult male and female participants with chronic plaque psoriasis involving between 2% and 20% body surface area (BSA) \[excluding the scalp, palms, and soles\] were recruited at 43 study sites in the United States and Canada.
| Milestone | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Started | 286 | 153 |
| Completed | 255 | 133 |
| Not completed | 31 | 20 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Lost to follow-up | 12 | 4 |
| Withdrew: Withdrawal by subject | 11 | 11 |
| Withdrew: Other | 1 | 2 |
The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented (observed data only) for each arm. Success was defined as achievement of an IGA score of 0 ('clear') or 1 ('almost clear') at Week 8, accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
| Participants | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 | 108 | 8 |
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The time to achieve PASI-50 (defined as a 50% reduction from baseline in PASI score) is presented, and is based on observed data only.
| days | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Time to Achieve Psoriasis Area Severity Index-50 (PASI-50) | 31.0 (29.0 to 41.0) | 104.0 (85.0 to NA) |
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. The number of participants achieving PASI-75 (defined as a 75% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.
| Participants | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Number of Participants Achieving Psoriasis Area Severity Index 75 (PASI-75) | 106 | 10 |
Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) \[higher scores indicate greater symptom severity\]. The number of participants achieving PASI-90 (defined as a 90% reduction from baseline in PASI score) at Week 8 is presented. Participant counts are based on observed data only.
| Participants | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Number of Participants Achieving Psoriasis Area Severity Index-90 (PASI-90) | 57 | 3 |
The number of participants achieving I-IGA success at Week 8 is presented. Success is defined as achievement of I-IGA score of 0 ('clear') or 1 ('almost clear') at Week 8 PLUS a ≥2-grade improvement in score from Baseline. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater symptom severity. Participant counts are based on observed data only.
| Participants | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Number of Participants Achieving Intertriginous IGA (I-IGA) Success at Week 8 | 37 | 4 |
The number of participants achieving an IGA score of 0 ('clear') at Week 8 is presented (observed data only) for each arm. The I-IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'); higher scores indicate greater symptom severity.
| Participants | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Number of Participants Achieving Score of 'Clear' in I-IGA at Week 8 | 33 | 3 |
The number of participants achieving success in WI-NRS is presented. Success is defined as achievement of a ≥ 4-point reduction in WI-NRS pruritus score in participants with WI-NRS pruritus score ≥ 4 at baseline. The WI-NRS is a 10 point scale ranging from 0 ('no itch') to 10 ('worst itch imaginable'), with higher scores indicating greater symptoms severity. Results are based on observed data only.
| Participants | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Week 2 Observed Data | 73 | 24 |
| Week 4 Observed Data | 101 | 18 |
| Week 8 Observed Data | 129 | 26 |
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The least squares (LS) mean (95% CI) change in PSD total score relative to baseline is presented for each treatment arm, with decreases from baseline indicating symptom improvement.
| score on a scale | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Week 4 | -43.5 (-48.2 to -38.9) | -17.7 (-23.5 to -11.9) |
| Week 8 | -50.1 (-55.0 to -45.1) | -19.2 (-25.3 to -13.0) |
Collected over Up to 121 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rofumilast Cream 0.3% | 0/286 (0%) | 2/286 (0.7%) | 0/286 (0%) |
| Vehicle Cream | 0/153 (0%) | 1/153 (0.7%) | 0/153 (0%) |
| Event | Rofumilast Cream 0.3% | Vehicle Cream |
|---|---|---|
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/286 | 1/153 |
| ConcussionInjury, poisoning and procedural complications | 1/286 | 0/153 |
| Foot fractureInjury, poisoning and procedural complications | 1/286 | 0/153 |
| Deformity thoraxMusculoskeletal and connective tissue disorders | 1/286 | 0/153 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/286 | 0/153 |
| Age, Continuous(years) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 47.6 ± 14.09 | 48.7 ± 15.77 | 48.0 ± 14.69 |
| Sex: Female, Male(Participants) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| Female | 97 | 57 | 154 |
| Male | 189 | 96 | 285 |
| Ethnicity (NIH/OMB)(Participants) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 63 | 34 | 97 |
| Not Hispanic or Latino | 223 | 119 | 342 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 5 |
| Asian | 21 | 11 | 32 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 8 | 8 | 16 |
| White | 234 | 124 | 358 |
| More than one race | 2 | 1 | 3 |
| Other | 15 | 8 | 23 |
| Whole Body Investigator Global Assessment (IGA) Baseline Score(Participants) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 |
| 1 - Almost Clear | 0 | 0 | 0 |
| 2 - Mild | 51 | 20 | 71 |
| 3 - Moderate | 206 | 122 | 328 |
| 4 - Severe | 29 | 11 | 40 |
| Intertriginous Area Investigator Global Assessment (I-IGA) Baseline Score(Participants) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 |
| 1 - Almost Clear | 5 | 1 | 6 |
| 2 - Mild | 33 | 16 | 49 |
| 3 - Moderate | 27 | 16 | 43 |
| 4 - Severe | 3 | 0 | 3 |
| Baseline Psoriasis Symptom Diary (PSD) Total Baseline Score(score on a scale) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 72.1 ± 42.75 | 73.4 ± 41.29 | 72.6 ± 42.21 |
| Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(Participants) | Rofumilast Cream 0.3% | Vehicle Cream | Total |
|---|---|---|---|
| 0 | 16 | 12 | 28 |
| 1 | 11 | 5 | 16 |
| 2 | 14 | 11 | 25 |
| 3 | 26 | 10 | 36 |
| 4 | 26 | 7 | 33 |
| 5 | 32 | 14 | 46 |
| 6 | 37 | 26 | 63 |
| 7 | 34 | 20 | 54 |
| 8 | 49 | 23 | 72 |
| 9 | 20 | 19 | 39 |
| 10 | 20 | 6 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Nov 2020, 10 months.
Results were first posted in Nov 2022, 1 year 11 months after primary completion. A results delay was requested in Sep 2021.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →